LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Home・Lista de Ações・Lisata Therapeutics

L
Lisata Therapeutics

Fechado

4.39 -0.23

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.37

Máximo

4.42

Indicadores-chave
By Trading Economics
Funcionários	26

Dividendos
By Dow Jones
Próximos Ganhos	26 de fev. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	13M 34M
Abertura anterior	4.62
Fecho anterior	4.39

Lisata Therapeutics Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de fev. de 2026, 23:07 UTC

Ganhos

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 de fev. de 2026, 23:01 UTC

Ganhos

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 de fev. de 2026, 22:59 UTC

Ganhos

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 de fev. de 2026, 22:42 UTC

Ganhos

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 de fev. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 de fev. de 2026, 23:46 UTC

Conversa de Mercado

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 de fev. de 2026, 23:36 UTC

Conversa de Mercado

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 de fev. de 2026, 23:30 UTC

Conversa de Mercado

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 de fev. de 2026, 23:20 UTC

Conversa de Mercado

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 de fev. de 2026, 23:20 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

24 de fev. de 2026, 23:16 UTC

Ganhos

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 de fev. de 2026, 23:13 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 de fev. de 2026, 23:12 UTC

Ganhos

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 de fev. de 2026, 23:10 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 de fev. de 2026, 23:10 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 de fev. de 2026, 23:08 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 de fev. de 2026, 23:07 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 de fev. de 2026, 22:52 UTC

Ganhos

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 de fev. de 2026, 22:46 UTC

Ganhos

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 de fev. de 2026, 22:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Warner Receives New Bid From Paramount -- 3rd Update

24 de fev. de 2026, 22:29 UTC

Ganhos

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 de fev. de 2026, 22:28 UTC

Ganhos

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 de fev. de 2026, 22:27 UTC

Ganhos

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 de fev. de 2026, 22:27 UTC

Ganhos

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 de fev. de 2026, 22:25 UTC

Ganhos

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 de fev. de 2026, 22:24 UTC

Ganhos

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 de fev. de 2026, 22:23 UTC

Ganhos

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 de fev. de 2026, 22:22 UTC

Ganhos

Woolworths Interim Dividend 45 Australian Cents/Share

24 de fev. de 2026, 22:22 UTC

Ganhos

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24 de fev. de 2026, 22:21 UTC

Ganhos

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Comparação entre Pares

Variação de preço

Lisata Therapeutics Previsão

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para Lisata Therapeutics - Dist nos últimos 3 meses.

Informação Financeira

Sobre Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.